Drug Trial Radar · NCT01207011
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Apr 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
202
Actual
Start
Oct 2010
Primary completion
Jun 2014
Study completion Jun 2014
Sponsor
- Lead sponsor
- Sumitomo Pharma Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).
Conditions
- Lung Cancer
Interventions
Amrubicin hydroclorideDrug
AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.
DocetaxelDrug
DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression free survivalTime frame: 3.3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
32 Sites
Multiple Locations, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.